Drug Discovery Weekly — April 4, 2026

FDA & Regulatory Decisions

1. Foundayo™ (orforglipron) — Weight Loss/Obesity | Eli Lilly On April 1, the U.S. FDA approved Eli Lilly's Foundayo™ (orforglipron), the first oral GLP-1 receptor agonist for weight loss. The approval is a milestone in the GLP-1 drug class, which has dominated metabolic disease treatment but previously required subcutaneous injection. The pill format represents a potentially transformative shift in patient accessibility and adherence for obesity and weight management indications.

2. FDA Approvals Under Review — Alzheimer's, FSGS, HIV, Hematological Malignancies Multiple treatments are currently under FDA review with April 2026 decision dates, including candidates for Alzheimer's disease agitation, focal segmental glomerulosclerosis (FSGS), HIV-1, and obesity. Additional oncology agents are also expected, with Q2 2026 shaping up to be one of the most active quarters in recent memory for FDA action.

3. Q2 2026 Oncology Decisions — Dato-DXd in TNBC, Orca-T in Blood Cancers Targeted Oncology highlights two particularly consequential FDA decisions expected in Q2 2026: Dato-DXd (datopotamab deruxtecan) in triple-negative breast cancer (TNBC) and Orca-T in blood cancers. These are described as having potential to "transform survival outcomes and precision oncology care." Advisory committee meetings and PDUFA dates remain closely watched catalysts for the broader oncology community.

1 sources

endocrinenews.endocrine.org

endocrinenews.endocrine.org

Clinical Trial Spotlight

1. Capricor Therapeutics — Deramiocel in Duchenne Muscular Dystrophy (Phase 3 HOPE-3) Capricor Therapeutics announced positive topline results from its pivotal Phase 3 HOPE-3 study of deramiocel in Duchenne muscular dystrophy (DMD). The randomized, double-blind, placebo-controlled trial (n=106) met both its primary endpoint (Performance of Upper Limb v2.0, PUL v2.0) and the key secondary cardiac endpoint (left ventricular ejection fraction, LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively). This is a meaningful win for the DMD community, a disease with few effective disease-modifying options.

2. Karyopharm — Selinexor (SENTRY Trial) in Myelofibrosis (Phase 3) Karyopharm's Phase 3 SENTRY trial in myelofibrosis met its first co-primary endpoint, demonstrating a statistically significant improvement in spleen volume reduction. The result was reported on March 24, 2026. Notably, across other secondary and exploratory endpoints — including progression-free survival, hemoglobin stabilization, and bone marrow fibrosis improvement — no meaningful difference was observed between arms, a nuance that will likely shape regulatory and commercial discussions.

3. Early 2026 Neurology Trial Readouts — Alzheimer's Disease (CDR-SB Primary) NeurologyLive highlighted key neurology trial readouts to watch in early 2026, including Alzheimer's disease studies with the Clinical Dementia Rating-Sum of Boxes (CDR-SB) as the primary endpoint (baseline mean score: 3.45 ± 1.70). Secondary outcomes including the ADAS-Cog-13 (Alzheimer's Disease Assessment Scale – Cognitive Subscale, 13-item) are also being tracked. These data readouts are expected to shape treatment paradigms in early-to-moderate Alzheimer's.

Deals & Pipeline Moves

1. Biogen Acquires Apellis Pharmaceuticals — $5.6 Billion Biogen has entered a $5.6 billion agreement to acquire Apellis Pharmaceuticals, following clinical success for Apellis's complement pathway therapies. The deal brings two marketed complement therapies — systegene pegcetacoplan (Empaveli/Syfovre) — into Biogen's portfolio, significantly strengthening its immunology franchise. Analysts describe the deal as part of an accelerating M&A wave following a "flurry of deals" from Eli Lilly, Merck, and Biogen over the past week, with further consolidation predicted from Novartis, Amgen, and AbbVie.

2. U.S. Pharma Reaches $2.75 Billion Deal With China-Based Biotech for AI-Developed Drugs A major U.S. pharmaceutical company has reached a $2.75 billion collaboration deal with a China-based biotech company focused on AI-developed drugs. The deal was described in terms of exploring "novel mechanisms and accelerating the identification of promising therapeutic candidates." This fits within the broader 2026 theme of AI-generated drug discovery entering pivotal clinical stages, with 15–20 AI-discovered compounds expected to reach Phase 3 this year.

2 sources

biospace.com

s, including Novartis, Amgen and AbbVie.

static.biospace.com

static.biospace.com

Analysis: Development of the Week

Foundayo™ Approval: The Oral GLP-1 Era Begins

The FDA's approval of Eli Lilly's Foundayo™ (orforglipron) is arguably the single most consequential regulatory decision in metabolic disease in years — and possibly the most commercially significant pharma event of 2026 so far.

The GLP-1 receptor agonist class has revolutionized obesity and diabetes treatment since semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) entered mainstream use. However, a persistent barrier has been the requirement for weekly injections, which limits adoption among needle-averse patients and creates healthcare infrastructure demands for injection training and cold-chain storage. An oral GLP-1 pill eliminates these frictions at a stroke.

Competitive Landscape: Novo Nordisk's oral semaglutide (Rybelsus) is already approved for Type 2 diabetes, but its absorption requirements — taken on an empty stomach with minimal water — have constrained real-world uptake. Orforglipron's mechanism as a small-molecule, non-peptide GLP-1 agonist means it does not share those pharmacokinetic constraints, potentially giving it a meaningful real-world convenience advantage. If clinical efficacy translates to the commercial setting, this could reshape market share dynamics in obesity pharmacotherapy.

Patient Impact: The approval opens the GLP-1 class to a substantially larger patient pool. Patients who declined injection-based therapy due to needle phobia, cost concerns around specialty pharmacy administration, or logistical barriers now have a pill-format option. Given that obesity affects more than 40% of U.S. adults and remains dramatically undertreated even with injectable GLP-1s on the market, the addressable population for an oral option is enormous.

Broader Implications: The Foundayo™ approval also validates the small-molecule GLP-1 agonist approach, potentially opening the door for pipeline candidates from other companies pursuing the same mechanism. It underscores that the GLP-1 story — far from peaking — continues to evolve in directions that could fundamentally change chronic disease management.

What to Watch

1. Dato-DXd (datopotamab deruxtecan) PDUFA / AdCom — Q2 2026 (Triple-Negative Breast Cancer): One of the most closely watched oncology regulatory events of the quarter. A positive decision would expand the antibody-drug conjugate landscape in a notoriously difficult-to-treat indication.

2. Orca-T FDA Decision — Q2 2026 (Blood Cancers): Orca Bio's engineered T-cell therapy for blood cancers represents a precision cell therapy approach. Analysts view this as a potential transformation in hematologic malignancy care.

3. Karyopharm Selinexor SENTRY Secondary Endpoint Data — Myelofibrosis: With the spleen volume reduction co-primary now met, full data presentation including overall survival and progression-free survival trends will be critical for regulatory strategy and commercial positioning.

4. Neurology Alzheimer's Data Readouts — Early/Mid 2026: Multiple Alzheimer's trials with CDR-SB as the primary endpoint are approaching readout windows. Given the competitive intensity in early AD treatment — and the recent regulatory scrutiny of amyloid-targeting agents — any significant positive data will have outsized market impact.

5. Phase 3 Completion Wave — April 2026: A significant cohort of Phase 3 trials have primary completion dates in April 2026. Investors and drug developers should monitor the FDA Tracker for emerging topline results across oncology, rare disease, and metabolic indications.